Anti-influenza therapeutics remain essential for the control of influenza infections, which may require hospitalization for the most severe cases.

Six ESWI Board Members, led by Prof. Florian Krammer, together with a long list of prominent European scientists specialised in virology, immunology and epidemiology, have recently published a commentary in The Lancet Infectious Diseases.

This commentary highlights the potential need to incorporate neuraminidase components into future influenza vaccines

Estimates of current mid-season flu vaccine effectiveness (VE) in Europe and China range from 32% to 58% overall, with greater protection against influenza B than A, according to three studies published in Eurosurveillance.

This could facilitate pooled analyses linking viral genetic sequencing data to clinical severity, bringing insights to inform influenza surveillance and the vaccine strain selection process.

WHO announced them at the meeting on the composition of Influenza Virus Vaccines. These gatherings are held twice a year, bringing together an advisory group of experts from WHO Collaborating Centres and WHO Essential Regulatory Laboratories.

ECDC has launched an online platform, RespiCompass, which uses mathematical modelling to simulate respiratory disease dynamics under different scenarios.

Strengthening of nonpharmaceutical interventions changed the epidemic dynamics of pediatric infectious diseases, with a trend toward older hospitalized children.